Carregant...
Elotuzumab as a novel anti-myeloma immunotherapy
Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches. Elotuzumab is a humanized monoclonal antibody targeting CS1, which is a member of the SLAM (Signaling Lymph...
Guardat en:
| Publicat a: | Hum Vaccin Immunother |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5557243/ https://ncbi.nlm.nih.gov/pubmed/28604269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1327487 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|